Quek SC, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int J Gynecol Cancer. 2013;23(1):148-156. doi:10.1097/IGC.0b013e31827670fd

de Martel, C., et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer, 2017, 141: 664-670. https://doi.org/10.1002/ijc.30716

Iftner, Thomas et al. “Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.” Journal of clinical microbiology vol. 57,1 e01177-18. 2 Jan. 2019, doi:10.1128/JCM.01177-18

Weston, Georgie et al. “Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation.” BMJ open vol. 10,3 e031303. 8 Mar. 2020, doi:10.1136/bmjopen-2019-031303

Arbyn, Marc et al. “2020 list of human papillomavirus assays suitable for primary cervical cancer screening.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 27,8 (2021): 1083-1095. doi:10.1016/j.cmi.2021.04.031

Forslund, Ola et al. “HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri.” International journal of cancer vol. 144,5 (2019): 1073-1081. doi:10.1002/ijc.31819

Arbyn, M et al. “Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 21,9 (2015): 817-26. doi:10.1016/j.cmi.2015.04.015

Cuzick, J et al. “Comparing the performance of six human papillomavirus tests in a screening population.” British journal of cancer vol. 108,4 (2013): 908-13. doi:10.1038/bjc.2013.22